Vanda Pharmaceuticals Inc (NAS:VNDA)
$ 4.79 -0.06 (-1.24%) Market Cap: 279.21 Mil Enterprise Value: -96.54 Mil PE Ratio: 0 PB Ratio: 0.51 GF Score: 79/100

Q2 2019 Vanda Pharmaceuticals Inc Earnings Call Transcript

Jul 31, 2019 / 08:30PM GMT
Release Date Price: $12.45 (-1.58%)
Operator

Good day, ladies and gentlemen, and welcome to Vanda Pharmaceuticals Second Quarter 2019 Earnings Conference Call.

(Operator Instructions)

I'd now like to introduce one of your hosts for today's conference, Jim Kelly, Executive Vice President and Chief Financial Officer. You may begin.

James Patrick Kelly
Vanda Pharmaceuticals Inc. - Executive VP, CFO & Treasurer

All right. Thank you, Tiffany. Good afternoon and thank you for joining us to discuss Vanda Pharmaceuticals' Second Quarter 2019 performance. Second quarter 2019 results were released this afternoon and are available on the SEC's EDGAR System and on our website, www.vandapharma.com. In addition, we are providing live and archived versions of this conference call on our website.

Joining me on today's call is Dr. Mihales Polymeropoulos, our President and CEO. Following my introductory remarks, Mihales will update you on our ongoing activities. I will then comment on our financial results before opening

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot